BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US
Read more on the Boehringer Ingelheim launched Animal Health vaccine, aimed at protecting poultry from three different diseases.
Search
Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US
Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.
Biosimilars
Biosimilars
Focus on Alliance Management
Focus on Alliance Management
Transition to renewable energy signals a broader commitment to environmental sustainability
Transition to renewable energy signals a broader commitment to environmental sustainability
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Reducing Stress in Horses – With Music
Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".
Our Partners: ViraTherapeutics
Our Partners: ViraTherapeutics
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US
The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.
US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack
US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
Asthmatic Horse's First Inhaled Therapy | Boehringer Ingelheim US
Click here to read about Boehringer Ingelheim launching the first inhaled therapy for horses suffering with severe asthma in the United States.
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
FDA Grants BTD for Investigational Treatment of CIAS | BI US
Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.